Skip to Content

'
E. Scott Kopetz, MD, PhD, FACP

Present Title & Affiliation

Primary Appointment

Assistant Professor, Department of Gastrointestinal (GI) Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Education & Training

Degree-Granting Education

2009 University of Texas, Graduate School of Biomedical Sciences, Houston, TX, PhD, Patient Oriented Biological Research/Cancer Biology
2001 Johns Hopkins School of Medicine, Baltimore, MD, MD, Medicine
1997 Vanderbilt University, Nashville, TN, BE, Summa Cum Laude, Biomedical Engineering/ Electrical Engineering

Postgraduate Training

7/2004-6/2006 Fellowship, Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, Robert Wolff
7/2001-6/2004 Residency, Internal Medicine, Duke University Medical Center, Durham, NC, Diana McNeil

Board Certifications

10/2006 Medical Oncology
10/2004 Internal Medicine

Selected Publications

Peer-Reviewed Original Research Articles
1. Yang H, Higgins B, Kolinsky K, Packman K, Bradley WD, Lee RJ, Schostack K, Simcox ME, Kopetz S, Heimbrook D, Lestini B, Bollag G, Su F. Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer. Cancer Res. e-Pub 12/2011. PMID: 22180495.
2. Boonsirikamchai P, Asran MA, Maru DM, Vauthey JN, Kaur H, Kopetz S, Loyer EM. CT Findings of Response and Recurrence, Independent of Change in Tumor Size, in Colorectal Liver Metastasis Treated With Bevacizumab. AJR Am J Roentgenol 197(6):W1060-6, 12/2011. PMID: 22109320.
3. Bollag G, Mills GB, Desai J, Gallick G, Davies M and Kopetz S. Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with P13K inhibition or demethylating agents. Clinical Cancer Research (in review), 12/2011. e-Pub 12/2011.
4. Brouquet A, Overman MJ, Kopetz S, Maru DM, Loyer EM, Andreou A, Cooper A, Curley SA, Garrett CR, Abdalla EK, Vauthey JN. Is resection of colorectal liver metastases after a second-line chemotherapy regimen justified? Cancer 117(19):4484-92, 10/1/2011. e-Pub 3/28/2011. PMCID: PMC3128184.
5. Ferrarotto R, Pathak P, Maru D, Agarwal A, Overman M, Hoff PM, Kopetz S. Durable complete responses in metastatic colorectal cancer treated with chemotherapy alone. Clin Colorectal Cancer 10(3):178-82, 9/2011. e-Pub 4/24/2011. PMID: 21855039.
6. George B, Kopetz S. Predictive and Prognostic Markers in Colorectal Cancer. (Invited). Curr Oncol Rep 13(3):206-15, 6/2011. e-Pub 3/2011. PMID: 21373987.
7. Fogelman DR, Wolff RA, Kopetz S, Javle M, Bradley C, Mok I, Cabanillas F, Abbruzzese JL. Evidence for the Efficacy of Iniparib, a PARP-1 Inhibitor, in BRCA2-associated Pancreatic Cancer. Anticancer Res 31(4):1417-20, 4/2011. PMID: 21508395.
8. Brouquet A, Abdalla EK, Kopetz S, Garrett CR, Overman MJ, Eng C, Andreou A, Loyer EM, Madoff DC, Curley SA, Vauthey JN. High survival rate after two-stage resection of advanced colorectal liver metastases: response-based selection and complete resection define outcome. J Clin Oncol 29(8):1083-90, 3/10/2011. e-Pub 1/24/2011. PMCID: PMC3068054.
9. Tran B, Kopetz S, Tie J, Gibbs P, Jiang ZQ, Lieu CH, Agarwal A, Maru DM, Sieber O, Desai J. Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer. Cancer. e-Pub 3/31/2011. PMID: 21456008.
10. Ihle NT, Powis G, Kopetz S. PI-3-Kinase Inhibitors in Colorectal Cancer (Peer-reviewed Review). Curr Cancer Drug Targets 11(2):190-8, 2/2011. e-Pub 12/2010. PMID: 21158718.
11. Kim MP, Fleming JB, Wang H, Abbruzzese JL, Choi W, Kopetz S, McConkey DJ, Evans DB, Gallick GE. ALDH Activity Selectively Defines an Enhanced Tumor-Initiating Cell Population Relative to CD133 Expression in Human Pancreatic Adenocarcinoma. PLoS One 6(6):e20636, 2011. e-Pub 6/13/2011. PMCID: PMC3113804.
12. Maru DM, Kopetz S, Boonsirikamchai P, Agarwal A, Chun YS, Wang H, Abdalla EK, Kaur H, Charnsangavej C, Vauthey JN, Loyer EM. Tumor Thickness at the Tumor-normal Interface: A Novel Pathologic Indicator of Chemotherapy Response in Hepatic Colorectal Metastases. Am J Surg Pathol 34(9):1287-1294, 9/2010. e-Pub 8/2010. PMID: 20697255.
13. Kishi Y, Zorzi D, Contreras CM, Maru DM, Kopetz S, Ribero D, Motta M, Ravarino N, Risio M, Curley SA, Abdalla EK, Capussotti L, Vauthey JN. Extended Preoperative Chemotherapy Does Not Improve Pathologic Response and Increases Postoperative Liver Insufficiency After Hepatic Resection for Colorectal Liver Metastases. Ann Surg Oncol 17(11). e-Pub 6/2010. PMID: 20567921.
14. Silberfein EJ, Kattepogu KM, Hu CY, Skibber JM, Rodriguez-Bigas MA, Feig B, Das P, Krishnan S, Crane C, Kopetz S, Eng C, Chang GJ. Long-term Survival and Recurrence Outcomes Following Surgery for Distal Rectal Cancer. Annals of Surgical Oncology 17(11):2863-9, 6/2010. PMID: 20552409.
15. Brouquet A, Mortenson MM, Vauthey JN, Rodriguez-Bigas MA, Overman MJ, Chang GJ, Kopetz S, Garrett C, Curley SA, Abdalla EK. Surgical Strategies for Synchronous Colorectal Liver Metastases in 156 Consecutive Patients: Classic, Combined or Reverse Strategy? J Am Coll Surg 210(6):934-41, 6/2010. PMID: 20510802.
16. Overman MJ, Kopetz S, Lin E, Abbruzzese JL, Wolff RA. Is there a role for adjuvant therapy in resected adenocarcinoma of the small intestine. Acta Oncol 49(4):474-9, 5/2010. PMID: 20397775.
17. Overman MJ, Maru DM, Charnsangavej C, Loyer EM, Wang H, Pathak P, Eng C, Hoff PM, Vauthey JN, Wolff RA, Kopetz S. Oxaliplatin-Mediated Increase in Spleen Size As a Biomarker for the Development of Hepatic Sinusoidal Injury. J Clin Oncol 28(15):2549-2555, 4/2010. PMID: 20406923.
18. Lieu C, Kopetz S. The SRC family of protein tyrosine kinases: A new and promising target for colorectal cancer therapy. (Peer-reviewed Review). Clin Colorectal Cancer 9(2):89-94, 4/2010. PMID: 20378502.
19. Vauthey JN, Nordlinger B, Kopetz S, Poston G. Sequenced Chemotherapy and Surgery for Potentially Resectable Colorectal Liver Metastases: A Debate Over Goals of Research and an Approach While the Jury Remains Out. Ann Surg Oncol 17(8):1983-1986, 3/2010. PMID: 20232164.
20. Overman MJ, Pozadzides J, Kopetz S, Wen S, Abbruzzese JL, Wolff RA, Wang H. Immunophenotype and molecular characterisation of adenocarcinoma of the small intestine. Br J Cancer 102(1):144-50, 01/05/2010, 1/2010. PMID: 19935793.
21. Kopetz S, Hoff PM, Morris JS, Wolff RA, Eng C, Glover KY, Adinin R, Overman MJ, Valero V, Wen S, Lieu C, Yan S, Tran HT, Ellis LM, Abbruzzese JL, Heymach JV. Phase II Trial of Infusional Fluorouracil, Irinotecan, and Bevacizumab for Metastatic Colorectal Cancer: Efficacy and Circulating Angiogenic Biomarkers Associated With Therapeutic Resistance. Journal of Clinical Oncology 28(3):453-9, 1/2010. PMID: 20008624.
22. Chun YS, Vauthey JN, Boonsirikamchai P, Maru DM, Kopetz S, Palavecino M, Curley SA, Abdalla EK, Charnsangavej C, Loyer EM. Association of Computed Tomography Morphologic Criteria With Pathologic Response and Survival in Patients Treated With Bevacizumab for Colorectal Liver Metastases. JAMA 302(21):2338-2344, 12/2009. PMID: 19952320.
23. Slade JH, Alattar ML, Fogelman DR, Overman MJ, Agarwal A, Maru DM, Coulson RL, Charnsangavej C, Vauthey JN, Wolff RA, Kopetz S. Portal hypertension associated with oxaliplatin administration: clinical manifestations of hepatic sinusoidal injury. Clin Colorectal Cancer 8(4):225-30, 10/2009. PMID: 19822514.
24. Kopetz S, Chang G, Overman M, Eng C, Larson DW, Grothey A, Vauthey JN, Sargent D, McWilliams R. Improved Survival in Metastatic Colorectal Cancer is Associated with Sequential Adoption of Hepatic Resection and Improved Chemotherapy. J Clin Oncol 27(22):3677-83, 8/2009. e-Pub 5/2009. PMCID: PMC2720081.
25. Herman MP, Kopetz S, Bhosale PR, Eng C, Skibber JM, Rodriguez-Bigas MA, Feig BW, Chang GJ, Delclos ME, Krishnan S, Crane CH, Das P.. Sacral Insufficiency Fractures After Preoperative Chemoradiation for Rectal Cancer: Incidence, Risk Factors, and Clinical Course. Int J Radiat Oncol Biol Phys 74(3):818-23, 7/2009. e-Pub 1/2009. PMID: 19147305.
26. Rossi S, Kopetz S, Davuluri R, Hamilton SR, Calin GA. MicroRNAs, ultraconserved genes and colorectal cancers. (Invited). Int J Biochem Cell Biol 42(8):1291-1297, 6/2009. e-Pub 6/2009. PMID: 19497386.
27. Overman MJ, Varadhachary GR, Kopetz S, Adinin R, Lin E, Morris JS, Eng C, Abbruzzese JL, Wolff RA. Phase II study of Capecitabine and Oxaliplatin for Advanced Adenocarcinoma of the Small Bowel and Ampulla of Vater. J Clin Oncol 26(15S):4538, 6/2009. e-Pub 1/2009. PMID: 19164203.
28. Kopetz S, Lesslie DP, Dallas NA, Park SI, Johnson M, Parikh NU, Kim MP, Abbruzzese JL, Ellis LM, Chandra J, Gallick GE.. Synergistic activity of the SRC family kinase inhibitor dasatinib and oxaliplatin in colon carcinoma cells is mediated by oxidative stress. Cancer Res 69(9):3842-9, 5/2009. e-Pub 4/2009. PMCID: PMC2709758.
29. Kishi Y, Kopetz S, Chun YS, Palavecino M, Abdalla EK, Vauthey JN. Blood neutrophil-to-lymphocyte ratio predicts survival in patients with colorectal liver metastases treated with systemic chemotherapy. Ann Surg Oncol 16(3):614-22, 3/2009. e-Pub 1/2009. PMID: 19130139.
30. Kim MP, Park SI, Kopetz S, Gallick GE.. Src family kinases as mediators of endothelial permeability: effects on inflammation and metastasis. Cell Tissue Res 1(335):249-59, 1/2009. e-Pub 9/2008. PMID: 18815812.
31. Chang DZ, Kumar V, Ma Y, Li K, Kopetz S. Individualized Therapies in Colorectal Cancer: KRAS as a Marker for Response to EGFR-targeted Therapy (Invited Editorial). J Hematol Oncol 2(18):18, 2009. e-Pub 4/2009. PMCID: PMC2686726.
32. Fogelman DR, Kopetz S, Eng C. Emerging Drugs for Colorectal Cancer (Invited). Expert Opin Emerg Drugs 13(4):629-42, 12/2008. PMID: 19046131.
33. Blazer DG, Kish U, Maru DM, Kopetz S, Overman M, Fogelman D, Eng C, Chang DZ, Wang H, Zorzi D, Ribero D, Ellis LM, Glover K, Wolff RA, Curley SA, Abdalla EK, Vauthey JN. Pathologic Response to Preoperative Chemotherapy: A New Outcome End Point after Resection of Hepatic Colorectal Metastases. J Clin Oncol 59(33):5344-51, 11/2008. e-Pub 10/2008. PMID: 18936472.
34. Kesmodel SB, Ellis LM, Lin E, Chang GJ, Abdalla EK, Kopetz S, Vauthey JN, Rodriguez-Bigas MA, Curley SA, Feig BW. Preoperative bevacizumab does not significantly increase postoperative complication rates in patients undergoing hepatic surgery for colorectal cancer liver metastases. J Clin Oncol 26(32):5254-60, 11/2008. e-Pub 10/2008. PMID: 18854565.
35. Overman MJ, Kopetz S, Wen S, Hoff PM, Fogelman D, Morris J, Abbruzzese JL, Ajani JA, Wolff RA. Chemotherapy with 5-fluorouracil and a platinum compound improves outcomes in metastatic small bowel adenocarcinoma. Cancer 113(8):2038-45, 10/2008. PMID: 18759326.
36. Overman MJ, Kopetz S, Varadhachary G, Fukushima M, Kuwata K, Mita A, Wolff RA, Hoff P, Xiong H, Abbruzzese JL. Phase I clinical study of three times a day oral administration of TAS-102 in patients with solid tumors. Cancer Invest 26(8):794-9., 10/2008. PMID: 18798063.
37. Overman MJ, Varadhachary G, Kopetz S, Thomas MB, Fukushima M, Kuwata K, Mita A, Wolff RA, Hoff PM, Xiong H, Abburzzese JL. Phase I study of TAS-102 administered once daily on a 5-day-per-week schedule in patients with solid tumors. Invest. New Drugs 26(5), 10/2008. e-Pub 6/2008. PMID: 18528634.
38. Hoff PM, Kopetz S, Thomas MB, Langleben A, Rinaldi D, Anthony L, Wolff RA, Lassere Y, Abbruzzese JL. A phase II study of UFT with leucovorin administered as a twice daily schedule in the treatment of patients with metastatic colorectal cancer. Br J Cancer 99(5):722-6, 9/2008. e-Pub 8/2008. PMID: 18728662.
39. Overman MJ, Fogelman D, Al-Kali A, Crane CH, Evans D, Abdalla EK, Pisters P, Kopetz S, Eng C, Wolff RA. Aggressive combined modality therapy for recurrent colorectal cancer involving the duodenum and pancreas: a report of 5 cases. Clin Colorectal Cancer 7(5):338-42, 9/2008. PMID: 18794067.
40. Kauffman CR, Mahvash A, Kopetz S, Wolff RA, Ensor J, Wallace MJ. Partial splenic embolization for cancer patients with thrombocytopenia requiring systemic chemotherapy. Cancer 14(10):2283-8, 5/2008. PMID: 18344210.
41. Kopetz S, Overman M, Chang DZ, Glover KY, Shureiqi I, Wolff RA, Abbruzzese JL, Eng C. Systematic Survey of Therapeutic Trials for Metastatic Colorectal Cancer: Room for Improvement in the Critical Pathway. J Clin Oncol 26(12):2000-5, 4/2008. PMID: 18421052.
42. Kopetz S, Freitas D, Calabrichi A, Hoff PM. Adjuvant Chemotherapy for Stage II Colon Cancer (Peer-Reviewed Review). Oncology 22(3):260-70, 3/2008. PMID: 18494354.
43. Dhillon N, Kopetz S, Pei BL, Fabbro ED, Zhang T, Bruera E. Clinical findings of a palliative care consultation team at a comprehensive cancer center. J Palliat Med 11(2):191-7, 3/2008. PMID: 18333733.
44. Politano S, Overman M, Pathak P, Chadha R, Glover K, Chang DZ, Wolff RA, Hoff PM, Abbruzzese J, Eng C, Kopetz S. Second-Line Chemotherapy Use in Metastatic Colon Cancer Varies by Disease Responsiveness. Clin Colorectal Cancer 1(1):55-9, 1/2008. PMID: 18279578.
45. Chun YS, Vauthey JN, Ribero D, Donadon M, Mullen JT, Eng C, Madoff DC, Chang DZ, Ho L, Kopetz S, Wei SH, Curley SA, Abdalla EK. Systemic Chemotherapy and Two-Stage Hepatectomy for Extensive Bilateral Colorectal Liver Metastases: Perioperative Safety and Survival. J Gastrointest Surg 11(11):1498-1505, 11/2007. e-Pub 9/2007. PMID: 17849166.
46. Kopetz S, Jimenez C, Tu SM, Sharma P. Pulmonary arteriovenous fistula in a patient with renal cell carcinoma. Eur Respir J 29(4):813-5, 12/2006. PMID: 17400880.
47. Kopetz S. Endothelin-1 as a Target For Therapeutic Intervention in Prostate Cancer (Invited). Invest New Drugs 20:173-82, 5/2002. PMID: 12099577.
48. Kopetz ES, TH Magnuson, MD Duncan, JS Bender, KD Lillemoe, TA Gordon, JL Cameron, JW Harmon. Complications of neglected cholelithiasis account for significant surgical mortality in the elderly. Surg Forum(52):489-91, 10/2000.
49. Kopetz S, Steele CD, Brandt J, Baker A, Kronberg M, Galik E, Steinberg M, Warren A, Lyketsos CG. Characteristics and outcomes of dementia residents in an assisted living facility. Int J Geriatr Psychiatry 15(7):586-93, 7/2000. PMID: 10918338.
50. Cheng MD, Nash TM, Kopetz ES. Retrieval of Aerosol Optical Thickness by Means of the Least-Median-Squares Robust Algorithm. Journal of Aerosol Science 30:805-17, 1/1999.
51. Walczak WJ, Xiao JM, Kopetz ES, Lease K, Grau H, Lee SP, Han MK, and Knutson JR. Golden Ruler: Very Long-Range Resonance Energy Transfer to Surface Plasmon Acceptors. Biophysical Journal, 72:367, 2/1997.

Invited Articles
1. Kopetz S. Novel Targets for Systemic Therapy of Colorectal Cancer. Clin Adv Hematol Oncol 6(1):38-40, 1/2008. PMID: 18322439.
2. Kopetz S, Shah AN, Gallick GE. SRC continues aging: current and future clinical directions. Clin Cancer Res 13(24):7232-6, 12/2007. PMID: 18094400.
3. Kopetz S. Targeting Src and Epidermal Growth Factor Receptor in Colorectal Cancer: Rationale and Progress Into the Clinic. Gastrointestinal Cancer Research 1:S37-41, 7/2007.
4. Kopetz S, Hoff PM. Cytotoxic chemotherapy for advanced colorectal cancer. Recent advances in management. Oncology (Williston Park) 19(13 Suppl 6):11-7, 11/2005. PMID: 16502665.
5. Kopetz S, Kim ES. Adjuvant Chemotherapy in Non-Small Cell Lung Cancer. American Journal of Oncology Review (Pulmonary Supplement):1-4, 2/2005.

Editorials
1. Kopetz S, Vauthey JN. Perioperative chemotherapy for resectable hepatic metastases. Lancet 371(9617):963-5, 3/2008. PMID: 18358910.
Other Articles
1. Lieu C, Heymach J, Overman M, Tran H, Kopetz S. Beyond VEGF: Inhibition of the Fibroblast Growth Factor Pathway and Antiangiogenesis. Clin Cancer Res 17(19):6130-9, 10/1/2011. e-Pub 9/27/2011. PMID: 21953501.

Abstracts
1. Chang G, Maru D, Agarwal A,Schlette E, Wolff R, Rodriguez-Bigas M, You N, Feig B, Kopetz S, Skibber J, Eng C. Histopathologic responses in primary tumors of patients with metastatic colorectal carcinoma after neoadjuvant systemic chemotherapy alone. 12th World Congress on Gastrointestinal Cancer, 6/2010.
2. Chang G, Maru D, Agarwal A, Schlette E, Wolff R, Rodriguez-Bigas M, You N, Feig B, Kopetz S, Skibber J, Eng C. Histopathologic responses in primary tumors of patients with metastatic colorectal carcinoma after neoadjuvant systemic chemotherapy alone. Annals of Oncology, 6/2010.
3. Kopetz S, Wu J, Davies M, Parikh N, Johnson F, Gallick G, Donato N. Synergistic activity of Src and EGFR inhibitors in colon cancer. AACR Annual Meeting (#4079), 2007.

Book Chapters
1. Kopetz S. Targeted Therapy in Cancer. In: Targeted Therapy for Colorectal Cancer. Ed(s) Razelle Kurzrock, Maurie Markman. Humana Press: United States, 101-24, 2008. PMID: 978-1-60327-423-4.
2. Kopetz S, Raber M, Abbruzzese J. Colorectal, Anal, and Unknown Primary Cancer (electronic web update). In: Cancer Medicine, 2006.

Letters to the Editor
1. Vauthey JN, Zorzi D, Kopetz S, Abdalla EK, Kishi Y, Blazer DG. Colorectal Hepatic Metastases: Adjuvant Chemotherapy and Survival Reply. J Clin Oncol 27(20):E20-E21, 7/2009.
2. Vauthey JN, Zorzi D, Kopetz S, Abdalla EK, Kishi Y, Blazer DG, III. Reply to Colorectal hepatic metastases: adjuvant chemotherapy and survival by D. Gallagher et al. J Clin Oncol 27(20):e20-1, 7/2009.
3. Kopetz S, Abbruzzese JL.. Hidden Biases in an Observational Study of Bevacizumab Beyond Progression. J Clin Oncol 27(10):1732-3, 4/2009. e-Pub 3/2009. PMID: 19255299.
4. Overman M, Kopetz S. First-Line Therapeutic Strategies in Metastatic Colorectal Cancer The Davies/Goldberg Article Reviewed. ONCOLOGY-NEW YORK 22(13):1482-1483, 11/2008.

Grant & Contract Support

Title: Integrating Genomics and epigenomics in Stage II and III Colon Cancer: Colon Cancer Integromics.
Funding Source: UT MD Anderson Cancer Center - Hogan Award
Role: Principal Investigator
Duration: 7/1/2011 - 6/30/2012
 
Title: Bevacizumab Modulation of Radiographic Response and Oxaliplatin-Associated Hepatic Toxicity
Funding Source: Roche
Role: Principal Investigator
Duration: 5/1/2011 - present
 
Title: PTEN-loss enriched Akt inhibition clinical study in colorectal cancer
Funding Source: Cancer Prevention & Research Institute of Texas (CPRIT)
Role: Principal Investigator
Duration: 5/1/2011 - 4/30/2014
 
Title: BRAF Mutations in Metastatic Colorectal Cancer
Funding Source: UTMDACC IRG
Role: Principal Investigator
Duration: 1/1/2011 - 12/31/2011
 
Title: Characterization of PTEN in Colorectal Cancer
Funding Source: Astrazeneca
Role: Principal Investigator
Duration: 12/16/2010 - 12/15/2011
 
Title: Evaluation of VEGF-C and VEGF-D in Patients with Metastatic Colorectal Cancer
Funding Source: Circadian Technologies Limited
Role: Principal Investigator
Duration: 2/1/2010 - 2/28/2012
 
Title: Investigator Initiated - Phase II study of second-line irinotecan plus brivanib, a dual tyrosine inhibitor of VEGFR and FGFR, in metastatic colorectal cancer patients enriched for elevated levels of plasma FGF following progression on bevacizumab-based treatment, Protocol
Funding Source: Bristol-Myers Squibb
Role: Co-Principal Investigator
Principal Investigator: Kopetz/Overman
Duration: 2010 - present
 
Title: Preclinical strategies for selection of patients with metastatic colon cancer susceptible to AZD0530 in combination with chemotherapy, Protocol
Funding Source: AstraZeneca
Role: Co-Principal Investigator
Principal Investigator: Gary Gallick
Duration: 9/1/2009 - 9/30/2013
 
Title: MicroRNAs and other non-coding RNAs in colorectal metastasis, R01, Protocol
Funding Source: NIH/NCI
Role: Co-Principal Investigator
Principal Investigator: Calin/Hamilton/Kopetz
Duration: 6/8/2009 - 6/30/2011
 
Title: Graduate Program in Cancer Metastasis Research: From Bench to Bedside, Protocol
Funding Source: UT Graduate Program Initiative
Role: Collaborator
Principal Investigator: Gallick
Duration: 6/1/2009 - present
 
Title: Assessment of Targeted Therapies Against Colorectal Cancer Umbrella, Protocol
Funding Source: Institute for Personalized Cancer Therapeutics
Role: Principal Investigator
Duration: 2009 - 2011
 
Title: Src Inhibition in Colorectal Cancer, K23, Protocol
Funding Source: NIH/NCI
Role: Principal Investigator
Duration: 9/1/2008 - 8/30/2013
 
Title: Career Development Award-Reversing Oxaliplatin Resistance with a Src Inhibitor in Colorectal Cancer, Protocol
Funding Source: American Society of Clinical Oncology (ASCO)
Role: Principal Investigator
Duration: 7/1/2008 - 6/30/2011
 
Title: Targeted Assessment of Antiangiogenic Therapy, Protocol
Funding Source: NIH/NCI
Role: Project Leader
Principal Investigator: James Abbruzzese
Duration: 1/1/2007 - 12/31/2008
 
Title: Phase I study of two week TAS-109 (nucleoside analogue), Protocol
Funding Source: Taiho
Role: Principal Investigator
Duration: 7/6/2006 - 3/31/2008
 
Title: NIH Extramural Loan Repayment Program, Protocol
Funding Source: NIH/NCI
Role: Principal Investigator
Duration: 2006 - present
 
Title: K12, Paul Calabresi Career Development Award for Clinical Oncology (Fellow: 2006-07, Faculty 2007-08), Protocol
Funding Source: NIH/NCI
Role: Investigator
Duration: 9/1/2005 - 8/30/2008
 
Title: MDACC Multidisciplinary Research Project, Protocol
Funding Source: MDACC
Role: Co-Investigator

Last updated: 1/12/2012